Patient views regarding cannabis use in chronic kidney disease and kidney failure: a survey study. Issue 4 (26th July 2022)

• Record Type: Journal Article
• Authors: Collister, David; Herrington, Gwen; Delgado, Lucy; Whitlock, Reid; Tennankore, Karthik; Tangri, Navdeep; Goupil, Remi; Nadeau-Fredette, Annie-Claire; Davison, Sara N; Wald, Ron; Walsh, Michael
• Is Part Of: Nephrology dialysis transplantation. Volume 38:Issue 4(2023)
• Page Start: 922
• Page End: 931
• Publication Date: 2022-07-26
• Subjects: cannabis -- kidney disease -- survey -- symptoms; Nephrology -- Periodicals; Hemodialysis -- Periodicals; Kidneys -- Transplantation -- Periodicals; Hemodialysis; Kidneys -- Transplantation; Nephrology; Periodicals; 616.61
• DOI: 10.1093/ndt/gfac226
• Languages: English
• ISSNs: 0931-0509

Abstract

ABSTRACT: Background: Cannabis is frequently used recreationally and medicinally, including for symptom management in patients with kidney disease. Methods: We elicited the views of Canadian adults with kidney disease regarding their cannabis use. Participants were asked whether they would try cannabis for anxiety, depression, restless legs, itchiness, fatigue, chronic pain, decreased appetite, nausea/vomiting, sleep, cramps and other symptoms. The degree to which respondents considered cannabis for each symptom was assessed with a modified Likert scale ranging from 1 to 5 (1, definitely would not; 5, definitely would). Multilevel multivariable linear regression was used to identify respondent characteristics associated with considering cannabis for symptom control. Results: Of 320 respondents, 290 (90.6%) were from in-person recruitment (27.3% response rate) and 30 (9.4%) responses were from online recruitment. A total of 160/320 respondents (50.2%) had previously used cannabis, including smoking [140 (87.5%)], oils [69 (43.1%)] and edibles [92 (57.5%)]. The most common reasons for previous cannabis use were recreation [84/160 (52.5%)], pain alleviation [63/160 (39.4%)] and sleep enhancement [56/160 (35.0%)]. Only 33.8% of previous cannabis users thought their physicians were aware of their cannabis use. More than 50% of respondents probably would or definitely would try cannabis for symptom control for all 10 symptoms. Characteristics independently associated with interest in trying cannabis for symptom control included symptom type (pain, sleep, restless legs), online respondent {β = 0.7 [95% confidence interval (CI) 0.1–1.4]} and previous cannabis use [β = 1.2 (95% CI 0.9–1.5)]. Conclusions: Many patients with kidney disease use cannabis and there is interest in trying cannabis for symptom control. Graphical Abstract: